Mosku Nasian, Heesen Philip, Studer Gabriela, Bode Beata, Spataro Vito, Klass Natalie D, Kern Lars, Scaglioni Mario F, Fuchs Bruno
Faculty of Medicine, University of Lucerne, 6000 Lucerne, Switzerland.
Swiss Sarcoma Network, 6000 Lucerne, Switzerland.
Cancers (Basel). 2022 Mar 23;14(7):1632. doi: 10.3390/cancers14071632.
The ratio of malignancy in suspicious soft tissue and bone neoplasms (RMST) has not been often addressed in the literature. However, this value is important to understand whether biopsies are performed too often, or not often enough, and may therefore serve as a quality indicator of work-up for a multidisciplinary team (MDT). A prerequisite for the RMST of an MDT is the assessment of absolute real-world data to avoid bias and to allow comparison among other MDTs. Analyzing 950 consecutive biopsies for sarcoma-suspected lesions over a 3.2-year period, 55% sarcomas were confirmed; 28% turned out to be benign mesenchymal tumors, and 17% non-mesenchymal tumors, respectively. Of these, 3.5% were metastases from other solid malignancies, 1.5% hematologic tumors and 13% sarcoma simulators, which most often were degenerative or inflammatory processes. The RMST for biopsied lipomatous lesions was 39%. The ratio of unplanned resections was 10% in this series. Reorganizing sarcoma work-up into integrating practice units (IPU) allows the assessment of real-world data with absolute values over the geography, thereby enabling the definition of quality indicators and addressing cost efficiency aspects of sarcoma care.
可疑软组织和骨肿瘤的恶性率（RMST）在文献中并不常被提及。然而，该数值对于理解活检是否进行得过于频繁或不够频繁很重要，因此可作为多学科团队（MDT）检查工作的质量指标。MDT的RMST的一个先决条件是评估绝对的真实世界数据，以避免偏差并允许与其他MDT进行比较。在3.2年的时间里，对950例连续的疑似肉瘤病变进行活检分析，确诊为肉瘤的占55%；结果分别有28%为良性间叶性肿瘤，17%为非间叶性肿瘤。其中，3.5%是其他实体恶性肿瘤的转移灶，1.5%是血液系统肿瘤，13%是肉瘤模拟器，最常见的是退行性或炎症性病变。活检脂肪瘤样病变的RMST为39%。本系列中计划外切除率为10%。将肉瘤检查工作重组为整合实践单元（IPU），可以评估地理区域内具有绝对值的真实世界数据，从而能够定义质量指标并解决肉瘤治疗的成本效益问题。
